Results 151 to 160 of about 484,866 (343)
Bromocriptine in Parkinson’s Disease: Results Obtained With High and Low Dose Therapy [PDF]
J. David Grimes
openalex +1 more source
Parkinson’s Disease: Time, Place, Person and Survival
-
Weerasak Muangpaisan +3 more
openaire +1 more source
The MPTT‐nanozyme‐hydrogel system (Mn3O4@ChS‐HA) provides a multifunctional therapeutic strategy for intervertebral disc degeneration (IVDD), effectively targeting oxidative stress and enhancing AF repair by restoring extracellular matrix (ECM) and redox homeostasis.
Yangyang Chen +13 more
wiley +1 more source
In the last years, lysosomal storage diseases appear as a bridge of knowledge between rare genetic inborn metabolic disorders and neurodegenerative diseases such as Parkinson’s disease (PD) or frontotemporal dementia. Epidemiological studies helped
Emilia M. Gatto +4 more
doaj +1 more source
A unique 2D bionanozyme, engineered from a single amino acid and copper ions, demonstrates peroxidase‐mimicking catalytic activity. This efficient and simple bionanozyme allows for ultrasensitive, equipment‐free visual detection of key biomarkers in both test and real samples, meeting the WHO‐REASSURE standards for practical diagnostic applications ...
Subrat Vishwakarma +5 more
wiley +1 more source
Bromocriptine in the Management of End of Dose Deterioration in Parkinson’s Disease [PDF]
J. David Grimes +5 more
openalex +1 more source
Supplementary Materials and Methods. (PDF 401Â kb)
Majbour, Nour +13 more
openaire +1 more source
Transducer Materials Mediated Deep Brain Stimulation in Neurological Disorders
This review discusses advanced transducer materials for improving deep brain stimulation (DBS) in neurological disorders. These materials respond to light, ultrasound, or magnetic fields, enabling precise, less invasive neuromodulation. Their stimulus‐responsive properties enhance neural control and adaptive therapy, paving the way for next‐generation ...
Di Zhao +5 more
wiley +1 more source

